Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Author(s): Rong-Yan Guan, Xing-Ru Tang, Zou-Fang Huang*, Jun Du*, Xue-Hang Fu, Guang Lu and Wei-Wei Mou

DOI: 10.2174/0115748928247369231024112003

DownloadDownload PDF Flyer Cite As
Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review

Page: [121 - 130] Pages: 10

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Introduction: Splenic marginal zone Lymphoma (SMZL) is a rare, chronic B lymphocyte proliferative disease. Generally, SMZL is accompanied by circulating atypical villous lymphocytes, known as SMZL with villous lymphocytes. Rituximab is a chimeric monoclonal antibody to CD20; recent but limited studies have confirmed its effectiveness in treating SMZL. Given the low incidence and selection of treatment, statistical comparisons of rituximab monotherapy with other available treatment options with the full range of data from previous clinical studies remain sparse. Here, we report a case of SMZL with villous lymphocytes treated by rituximab monotherapy, which is especially infrequently reported.

Case Report: A 63-year-old Chinese female was presented to the hospital with complaints of splenomegaly and pain in the spleen area. Immunohistochemistry analysis was positive for IGH, IGK, and IGL clonal rearrangement. Villous lymphocytes were found in peripheral blood and bone marrow, along with further immunotyping results. The case was considered as SMZL with villous lymphocytes. Based on the SMZLSG prognosis assessment, we applied rituximab monotherapy. After eight cycles of rituximab treatment, the patient’s condition improved markedly, with blood constituent and size of the spleen returning to normal levels, achieving complete response, with no significant side effect observed.

Discussion: The patient provides a typical SMZL with villous lymphocytes case treated with rituximab monotherapy. Currently, the main treatment options include splenectomy and rituximab. After synthesizing a series of current views, we put forward our opinion about the selection of therapy for SMZL patients in order to gain maximum benefits for patients in need of treatment.

Conclusion: Our analysis found no statistically significant difference between rituximab monotherapy and rituximab combined with chemotherapy, while rituximab treatments resulted in better therapeutic effects than chemotherapy. Rituximab monotherapy has favorable therapeutic effects and minor adverse effects (AEs) in treating SMZL.

Keywords: Splenic marginal zone lymphoma, rituximab, monotherapy, case report, immunotargeted therapy, meta analysis.

[1]
Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: From genetics to management. Blood 2016; 127(17): 2072-81.
[http://dx.doi.org/10.1182/blood-2015-11-624312] [PMID: 26989207]
[2]
Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone lymphoma: A population-based study on the 2001–2008 incidence and survival in the United States. Leuk Lymphoma 2013; 54(7): 1380-6.
[http://dx.doi.org/10.3109/10428194.2012.743655] [PMID: 23101590]
[3]
Florindez JA, Alderuccio JP, Reis IM, Lossos IS. Splenic marginal zone lymphoma: A US population‐based survival analysis (1999‐2016). Cancer 2020; 126(21): 4706-16.
[http://dx.doi.org/10.1002/cncr.33117] [PMID: 32767702]
[4]
Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview. Pathologica 2010; 102(3): 83-7.
[PMID: 21171509]
[5]
Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22(3): 487-95.
[http://dx.doi.org/10.1038/sj.leu.2405068] [PMID: 18094718]
[6]
Tarella C, Arcaini L, Baldini L, et al. Italian society of hematology, italian society of experimental hematology, and italian group for bone marrow transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk 2015; 15(2): 75-85.
[http://dx.doi.org/10.1016/j.clml.2014.07.002] [PMID: 25108679]
[7]
Lenglet J, Traullé C, Mounier N, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 2014; 55(8): 1854-60.
[http://dx.doi.org/10.3109/10428194.2013.861067] [PMID: 24206091]
[8]
Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005; 75(2): 130-5.
[http://dx.doi.org/10.1111/j.1600-0609.2005.00426.x] [PMID: 16000129]
[9]
Lefrère F, Lévy V, François S, et al. Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: An update. Leukemia 2004; 18(11): 1924-5.
[http://dx.doi.org/10.1038/sj.leu.2403440] [PMID: 15385943]
[10]
Riccioni R, Caracciolo F, Galimberti S, Cecconi N, Petrini M. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003; 21(4): 163-8.
[http://dx.doi.org/10.1002/hon.717] [PMID: 14735554]
[11]
Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25(3): 127-31.
[http://dx.doi.org/10.1002/hon.820] [PMID: 17514771]
[12]
Bennett M, Yegena S, Dave HP, Schechter GP. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2008; 26(2): 114.
[http://dx.doi.org/10.1002/hon.844] [PMID: 18271062]
[13]
Iannitto E, Luminari S, Tripodo C, et al. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: A Fondazione Italiana Linfomi phase II study. Leuk Lymphoma 2015; 56(12): 3281-7.
[http://dx.doi.org/10.3109/10428194.2015.1029925] [PMID: 25791121]
[14]
Zhang S, Xuan Z, Zhang L, Lu J, Song P, Zheng S. Splenic marginal zone lymphoma: A case report and literature review. World J Surg Oncol 2020; 18(1): 259.
[http://dx.doi.org/10.1186/s12957-020-02030-3] [PMID: 33004051]
[15]
Montalbán C, Abraira V, Arcaini L, et al. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases. Br J Haematol 2012; 159(2): 164-71.
[http://dx.doi.org/10.1111/bjh.12011] [PMID: 22924582]
[16]
Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107(1): 125-35.
[http://dx.doi.org/10.1002/cncr.21931] [PMID: 16700034]
[17]
Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90(6): 856-8.
[PMID: 15951303]
[18]
Salles G, Barrett M, Foà R, et al. Rituximab in B-Cell hematologic malignancies: A review of 20 years of clinical experience. Adv Ther 2017; 34(10): 2232-73.
[http://dx.doi.org/10.1007/s12325-017-0612-x] [PMID: 28983798]
[19]
Banchereau J, Rousset F. Human B lymphocytes: Phenotype, proliferation, and differentiation. Adv Immunol 1992; 52: 125-262.
[http://dx.doi.org/10.1016/S0065-2776(08)60876-7] [PMID: 1442306]
[20]
a) Boross P, Leusen JH. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439(70778): 851-5.;
b) Weng WK, Levy R, Immunoglobulin G. Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma 2009; 50(9): 1494-500.
[PMID: 19672774]
[21]
Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: Progress report and comparison with splenectomy. Oncologist 2013; 18(2): 190-7.
[http://dx.doi.org/10.1634/theoncologist.2012-0251] [PMID: 23345547]
[22]
Else M, Marín-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012; 159(3): 322-8.
[http://dx.doi.org/10.1111/bjh.12036] [PMID: 23016878]
[23]
Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: Guidelines on malignant lymphoma. part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24(4): 857-77.
[http://dx.doi.org/10.1093/annonc/mds643] [PMID: 23425945]
[24]
Kalpadakis C, Pangalis GA, Sachanas S, et al. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leuk Lymphoma 2016; 57(11): 2705-8.
[http://dx.doi.org/10.3109/10428194.2016.1157877] [PMID: 27082039]
[25]
Kalpadakis C, Pangalis GA, Angelopoulou MK, Vassilakopoulos TP. Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol 2017; 30(1-2): 139-48.
[http://dx.doi.org/10.1016/j.beha.2016.07.004] [PMID: 28288709]
[26]
Xing KH, Kahlon A, Skinnider BF, et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol 2015; 169(4): 520-7.
[http://dx.doi.org/10.1111/bjh.13320] [PMID: 25854936]
[27]
Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84(9): 3047-53.
[http://dx.doi.org/10.1182/blood.V84.9.3047.3047] [PMID: 7949176]
[28]
Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347(2): 89-94.
[http://dx.doi.org/10.1056/NEJMoa013376] [PMID: 12110736]
[29]
Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Cancer 2004; 101(9): 2050-7.
[http://dx.doi.org/10.1002/cncr.20596] [PMID: 15389479]
[30]
Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients. Clin Lymphoma 2002; 3(1): 41-7.
[http://dx.doi.org/10.3816/CLM.2002.n.010] [PMID: 12141954]
[31]
LefrÈRe F, Hermine O, FranÇOis S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40(1-2): 113-7.
[http://dx.doi.org/10.3109/10428190009054887] [PMID: 11426611]
[32]
Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010; 34(2): 184-9.
[http://dx.doi.org/10.1016/j.leukres.2009.04.003] [PMID: 19414190]
[33]
Lefrère F, Hermine O, Belanger C, et al. Fludarabine: An effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14(4): 573-5.
[http://dx.doi.org/10.1038/sj.leu.2401710] [PMID: 10764141]
[34]
Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M. Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): Extended follow-up. Ann Oncol 2013; 24(9): 2434-8.
[http://dx.doi.org/10.1093/annonc/mdt181] [PMID: 23712547]
[35]
Chacón JI, Mollejo M, Muñoz E, et al. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100(5): 1648-54.
[http://dx.doi.org/10.1182/blood.V100.5.1648.h81702001648_1648_1654] [PMID: 12176884]
[36]
Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: Natural history and response to therapy in 50 cases. Br J Haematol 1991; 78(2): 206-9.
[http://dx.doi.org/10.1111/j.1365-2141.1991.tb04417.x] [PMID: 2064958]